在HR+患者中,HER2 零表达和 HER2 低表 达(对数秩检验 P=0.4285)之间的 RFS 曲线没有统计学差异(图3)。多变量分析发现,仅较高 的初始cAJCC分期(P=0.003)与较差的RFS独立相关(表 3)。对于HR+eBC患者的OS,单变量分析表明,只有cN...
近日,复旦大学附属肿瘤医院江一舟教授团队受国际肿瘤期刊Cancer Biology & Medicine杂志(IF=5.5)邀约,撰稿发表了名为“Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast can...
近日，来自美国耶鲁大学的Lajos Pusztai团队在Cancer Cell上在线发表题为Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial 的文章，报道了一项用于II/III期早期乳腺癌的I-SPY2试验结果，显示度伐利尤与奥拉帕尼联...
[3]Marhold M, Vaz-Batista M, Gión M, et al. Trastuzumab-deruxtecan in HER2-low metastatic breast cancer patients with newly diagnosed or progressing brain metastases: The TUXEDO-4 phase II trial. 2024 SABCS.P3-08-21. [4]Modi S, Jacot W, Yamashita T, et al. DESTINY-Breast04 Trial ...
2023年11月22日,复旦大学附属肿瘤医院余科达团队在美国临床研究协会JCI insight杂志在线发表了题为Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects的研究论文。该研究揭示了HER2低表达三阴性乳腺癌的分子特征,并探索该亚型乳腺癌治...
[5]Cortés J, Kim S, Chung W, et al. Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study. 2021 ESMO. LBA1. ...
[3]Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.[4]Müller V, Bachelot T, Curigliano G, et al. Expert consensus on the prevention of brain metastases in patients with HER2-...
2. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med.2020; 54(1): 34-44. 3. Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.Mol Biol In...
2.Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med.2020; 54(1): 34-44. 3.Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.Mol Biol Int....
2023年3月30日,空军军医大学第二附属医院普通外科包国强教授团队在乳腺癌期刊《Breast Cancer Research》发表了题为“Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low”的研究成果。该研究通过对三阴性乳腺癌(TNBC)患者进行为期8年的随访调查、并且...